DCF Advisers LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

DCF Advisers LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,113 shares of the company’s stock, valued at approximately $1,012,000.

Other hedge funds have also modified their holdings of the company. Atlantic Private Wealth LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $32,000. 25 LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $55,000. Horizons Wealth Management lifted its position in Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock worth $61,000 after purchasing an additional 346 shares during the period. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the second quarter valued at $66,000. Finally, Mcmillion Capital Management Inc. bought a new position in shares of Johnson & Johnson in the second quarter valued at $103,000. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. Barclays upped their price target on Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a report on Thursday, October 12th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 26th. Atlantic Securities upped their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Finally, HSBC assumed coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price target for the company. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $169.19.

Johnson & Johnson Trading Down 0.2 %

Shares of NYSE JNJ opened at $149.79 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $181.04. The firm has a 50 day moving average price of $154.77 and a two-hundred day moving average price of $160.38. The stock has a market cap of $360.59 billion, a P/E ratio of 11.12, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. The firm had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. As a group, equities analysts forecast that Johnson & Johnson will post 10.1 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 annualized dividend and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.